DC
ARCT icon

Davenport & Co’s Arcturus Therapeutics ARCT Stock Holding History

Davenport & Co’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,900
Closed -$369K – 1157
2024
Q3 		$369K Buy
15,900
+4,400
+38% +$94.1K ﹤0.01% 912
2024
Q2 		$280K Sell
11,500
-5,100
-31% -$155K ﹤0.01% 974
2024
Q1 		$561K Buy
16,600
+5,100
+44% +$181K ﹤0.01% 771
2023
Q4 		$363K Sell
11,500
-2,200
-16% -$52.3K ﹤0.01% 856
2023
Q3 		$350K Sell
13,700
-27,300
-67% -$841K ﹤0.01% 829
2023
Q2 		$1.18M Buy
41,000
+14,100
+52% +$384K 0.01% 515
2023
Q1 		$645K Buy
+26,900
New +$483K 0.01% 657

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Davenport & Co's ARCT Position: Q4 2024 in Review

Davenport & Co sold out of Arcturus Therapeutics (ARCT) in Q4 2024, closing a stake of 15,900 shares — an estimated $369K sold.

Davenport & Co first reported a position in ARCT in Q1 2023 and held it in 7 quarters. The position peaked at $1.18M in Q2 2023. 147 funds tracked by Wall St. Rank hold ARCT as of Q4 2024.

  • Davenport & Co reported no remaining Arcturus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Davenport & Co sold 15,900 Arcturus Therapeutics shares in Q4 2024, an estimated $369K.
  • Davenport & Co first reported a position in Arcturus Therapeutics in Q1 2023 and held it in 7 quarters.
  • Davenport & Co's Arcturus Therapeutics position peaked at $1.18M in Q2 2023.
  • 147 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2024.

Based on Davenport & Co's 13F filing for Q4 2024, filed 24 Jan 2025.